Evidence map›Paper›PMID 31173438›Full record

ArticleEnvironmental microbiology2019

Cwp22, a novel peptidoglycan cross-linking enzyme, plays pleiotropic roles in Clostridioides difficile.

Duolong Zhu, Jessica Bullock, Yongqun He, Xingmin Sun

Open access · bronzeAbstract read
In one paragraph

Article in Environmental microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 35 citations in OpenAlex.

  1. Microbial Biosensor for Sensing and Treatment of Intestinal Inflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  2. Control ofmBio · 2025
    Article
  3. Article
  4. Article
  5. Clinical microbiology reviews · 2024
    Review
  6. Article
  7. Le infezioni in medicina · 2024
    Review
  8. Review
  9. Article
  10. Non-Toxin-BasedPathogens (Basel, Switzerland) · 2023
    Article
  11. Review
  12. Microbiology (Reading, England) · 2023
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Host Immune Responses toFrontiers in microbiology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Duolong ZhuDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.ORCID 0000-0002-7322-6858
Jessica BullockDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Yongqun HeDepartment of Microbiology and Immunology, and Center for Computational Medicine and Bioinformatics, Unit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Xingmin SunDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
University of South Florida · USUniversity of Michigan · US

Funding

Multivalent vaccines against Clostridium difficile infectionR01AI132711 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI Xingmin Sun, Shifeng Wang · 2017 to 2026
$3.3M
Ontology-based Information Network to Support Vaccine ResearchR01AI081062 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HE, YONGQUN · 2009 to 2012
$1.1M
Signaling pathway of TNF-alpha production and Clostridium difficile infection (CDK01DK092352 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI SUN, XINGMIN · 2012 to 2016
$470k
Multivalent Bacillus mucosal vaccines against Clostridium difficile infectionR21AI113470 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI SUN, XINGMIN · 2015 to 2016
$438k
The role of tumor progression locus 2 (TPL2) in the pathogenesis of Clostridium difficile infection (CDI)R03DK112004 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI SUN, XINGMIN · 2017 to 2018
$154k
National Institutes of Health grants K01-DK092352, R21-AI113470, R03-DK112004,National Institutes of Health grants R01-AI132711, R01-AI081062NIAID NIH HHS R01 AI081062NIAID NIH HHS R01 AI132711NIAID NIH HHS R21 AI113470NIDDK NIH HHS K01 DK092352NIDDK NIH HHS R03 DK112004
6 · The paper itself

Abstract

Clostridioides difficile is a Gram-positive, spore-forming, toxin-producing anaerobe pathogen, and can induce nosocomial antibiotic-associated intestinal disease. While production of toxin A (TcdA) and toxin B (TcdB) contribute to the main pathogenesis of C. difficile, adhesion and colonization of C. difficile in the host gut are prerequisites for disease onset. Previous cell wall proteins (CWPs) were identified that were implicated in C. difficile adhesion and colonization. In this study, we predicted and characterized Cwp22 (CDR20291_2601) from C. difficile R20291 to be involved in bacterial adhesion based on the Vaxign reverse vaccinology tool. The ClosTron-generated cwp22 mutant showed decreased TcdA and TcdB production during early growth, and increased cell permeability and autolysis. Importantly, the cwp22 mutation impaired cellular adherence in vitro and decreased cytotoxicity and fitness over the parent strain in a mouse infection model. Furthermore, lactate dehydrogenase cytotoxicity assay, live-dead cell staining and transmission electron microscopy confirmed the decreased cell viability of the cwp22 mutant. Thus, Cwp22 is involved in cell wall integrity and cell viability, which could affect most phenotypes of R20291. Our data suggest that Cwp22 is an attractive target for C. difficile infection therapeutics and prophylactics.

Indexed as

AnimalsAnti-Bacterial AgentsBacterial AdhesionBacterial ProteinsBacterial ToxinsCell WallClostridioides difficileGene Expression Regulation, BacterialMiceMutationPeptidoglycanAnti-Bacterial AgentsBacterial ProteinsBacterial ToxinsPeptidoglycan

Identifiers

PMID31173438
PMCPMC7219524
OpenAlexW2948127891

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.